CMS ACCESS launched on July 5. Three weeks later, the conversation among ACO leaders has shifted from "what is this program?" to "what does it do to ours?" That is the right question. Most of the answers circulating are not.
This post separates the genuine strategic risks from the noise, walks through what we are hearing across three ACO archetypes, and lands on the one decision that determines whether ACCESS becomes a threat or an asset: who controls clinical continuity for your attributed population.
What Has Happened in the Three Weeks Since July 5
Close to 200 organizations enrolled as ACCESS participants before the July 5 launch. The majority are digital health platforms, virtual care companies, and consumer wellness apps, organizations that until July 5 had never served a Medicare fee-for-service population. They are now three weeks into enrolling your attributed beneficiaries directly, without a referral, without ACO sign-off, and with a care plan your organization may never see.
That last point is what ACO leaders keep raising. The concern is legitimate. The framing is often wrong.
The anxiety in the market sounds like this: ACCESS participants are enrolling our patients, managing their care outside our clinical infrastructure, and leaving us with no visibility and no revenue. Some of that is true. Not all of it is inevitable.
The Three ACO Archetypes We Are Hearing From
The ACO that sees ACCESS as an MSSP or REACH threat. This is the most common initial reaction. If a third party is managing our highest-risk attributed patients, will that show up in our benchmark? Will it affect our shared savings?
The short answer is no, not yet. CMS has confirmed ACCESS spending is excluded from MSSP and ACO REACH benchmark and performance year calculations for 2026 and 2027. The benchmark protection is real. What it does not protect is clinical visibility. An ACCESS participant managing a patient's CKD and hypertension between visits, without routing updates back to the ACO's care team, is a gap in care coordination that will show up in quality measures and readmission rates regardless of how the benchmark is calculated.
The ACO that sees ACCESS as a revenue opportunity. This is the more sophisticated read, and it is correct as far as it goes. CMS pays referring clinicians approximately $100 per patient per year for documented care coordination activity under ACCESS. For an ACO managing several thousand attributed Medicare beneficiaries with qualifying chronic conditions, that is a material new revenue line that requires no change to FFS billing and carries no outcome risk for the referring provider.
The gap in this framing is that co-management revenue only flows through a structured relationship with an ACCESS participant that delivers bidirectional PCP communication and a shared clinical record. An ACCESS participant that operates as a black box generates no co-management revenue for your providers and no clinical visibility for your care team. The revenue opportunity and the clinical risk are the same problem, solved by the same decision.
The ACO that is waiting to see how this plays out. This is the most dangerous posture, and it is also the most common among organizations with mature MSSP or REACH programs. The logic is understandable: we have built something that works, ACCESS is new and uncertain, and we do not want to move until the model stabilizes.
What that logic misses is that ACCESS enrollment has not been waiting for ACOs to decide. For three weeks, patients in your attributed population have been attesting to ACCESS participants. Every patient who has enrolled with a consumer wellness app is a patient whose medication changes, care plan updates, and specialist referrals may no longer route through your network. Over a 10-year program, three weeks of inaction already has a cost. It compounds from here.
What Clinical Continuity Actually Requires
The anxiety about ACCESS is, at its core, an anxiety about clinical continuity. The question every ACO should be asking is not "will ACCESS hurt my benchmark?" It is "can I still see what is happening with my highest-risk patients?"
The answer depends entirely on which ACCESS participant is managing those patients and whether that participant's operating model is built around the referring provider or around the patient in isolation.
An ACCESS participant that delivers structured care updates to referring providers within three days of care initiation, routes escalation alerts in real time, maintains a shared clinical record accessible through the ACO's existing EHR, and steers specialist referrals back into the ACO's network is not a threat to clinical continuity. It extends the ACO's care team between visits without displacing it.
An ACCESS participant that operates entirely outside the clinical record, delivers no bidirectional PCP communication, and treats the ACO as a bystander is a structural gap in care coordination, regardless of how the benchmark is protected.
This is the distinction ACCESS marketing has largely obscured. Every participant describes their program as patient-centered and clinically integrated. The operational test is straightforward: when a patient's blood pressure reading falls outside target range at 8pm on a Thursday, does anyone in the ACO's care team know about it before the patient's next scheduled appointment?
Where Innovaccer Sits in This Picture
Innovaccer operates through Story Health Partners, its CMS-accepted physician entity that launched as a first-cohort ACCESS participant on July 5. Story Health absorbs all outcome risk. If enrolled patients miss clinical targets, Innovaccer carries the financial consequence. The ACO and its providers do not.
Care delivery runs on Adaptive Program Intelligence™, which dynamically adjusts intervention intensity in real time based on each patient's engagement signals and clinical trajectory. Patients who are stable receive AI-led monitoring. Patients whose readings drift move into a hybrid coaching pathway. Patients with rising clinical risk receive high-touch clinical support and direct escalation, with the referring provider notified through their existing EHR within three days of any escalation event, and in real time for acute deterioration.
For ACOs already on the Innovaccer platform, ACCESS activates as an extension of existing infrastructure. With Atlas, the Population Health Operating System™ ACOs can identify the full eligible attributed population across Early CKM and Advanced CKM tracks without manual review, turning eligibility into enrolled patients through automated outreach rather than waiting for referrals that may never arrive.
The partnership principle is straightforward: Innovaccer delivers the care between visits. The ACO's providers retain the clinical relationship, the co-management revenue, and the referral volume. The patient stays in the network.
The Decision That Is Already Three Weeks Overdue
Three weeks into ACCESS, the ACOs best positioned for the next 10 years are not the ones with the most sophisticated benchmark models. They are the ones that have already decided who will manage their highest-risk attributed patients between visits, and ensured that the partner keeps every clinical decision visible to their providers.
That decision does not get cleaner the longer it waits. Enrollment has been open since July 5, and patients are attesting every day. The population available for a structured ACO partnership is smaller today than it was three weeks ago.
ACCESS is not a threat to ACOs that prioritize clinical continuity. It is a compounding liability for those who do not.
To know more, register for our on-demand webinar: Navigating ACCESS and LEAD: Two CMS Models, One Partner.